Postpartum initiation of GLP-1 receptor agonists among commercially insured women in the us

New research finds that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of death and major cardiovascular events in psoriasis patients. GLP-1RAs also show promise in reducing alcohol and substance abuse, with a 65% lower risk of alcohol abuse.

A controlled study found that GLP-1 receptor agonists increase the risk of nail detachment and disorders by 4 times, compared to those with obesity or type 2 diabetes. Additionally, hair and scalp changes were also significantly more common among GLP-1 users.

Researchers found that GLP-1 receptor agonists decrease whole-body fat mass by about 7.9 kg for every unit reduction in BMI, while muscle mass decreases by 6.4 kg. This suggests that GLP-1 receptor agonists are more effective at reducing overall body fat than muscle mass.

A new study found that Medicaid Accountable Care Organizations (ACOs) in Massachusetts increased prenatal and postpartum office visits, postpartum depression screenings, and timely postpartum care. This value-based model of care addressed inequities in healthcare access for pregnant and postpartum people covered by Medicaid.

A growing number of patients on GLP-1 receptor agonists may experience altered FDG uptake patterns on oncological PET-CT scans, potentially leading to misdiagnosis. Researchers recommend documenting medication histories to inform interpretation and developing national guidance.

The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.